丁脒肟 | 27620-10-6

• 物质功能分类: 有机原料 - 氨基化合物 - 无环单胺、多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 丁脒肟
• 英文名称: butyramide oxime
• 英文别名: N'-hydroxybutyrimidamide；N'-hydroxybutanimidamide
• CAS: 27620-10-6
• 化学式: C₄H₁₀N₂O
• mdl: MFCD05663152
• 分子量: 102.136
• InChiKey: OPENCMFJZQABIY-UHFFFAOYSA-N

物化性质

• 沸点：
  89 °C
• 稳定性/保质期：
  如果遵照规格使用和储存，则不会分解。避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  T
• 安全说明：
  S45
• 危险类别码：
  R25
• 海关编码：
  2925290090
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密的容器中，存放在阴凉、干燥的地方。

SDS

Name:	n-Hydroxy-butyramidine Material Safety Data Sheet
Synonym:	None Known
CAS:	27620-10-6

Section 1 - Chemical Product MSDS Name:n-Hydroxy-butyramidine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
27620-10-6	n-Hydroxy-butyramidine	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 27620-10-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: Beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 89 deg C @0.5mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H10N2O
Molecular Weight: 102.14

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Acid chlorides, strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 27620-10-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
n-Hydroxy-butyramidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 27620-10-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 27620-10-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 27620-10-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

丁脒肟

概述 丁脒肟是一种医药中间体，可通过将丁腈与羟胺盐酸盐反应制备得到。文献报道显示，丁脒肟可用于制备PI3抑制剂。

应用 丁脒肟作为有机合成和医药中间体，在实验室研发及化工医药合成过程中均有广泛应用。

制备 将4.000g（57.878mmol）的丁腈、2.315g（57.878mmol）的NaOH 和4.022g（57.878mmol）的羟胺盐酸盐混合，加入95％乙醇（15mL）和水（2mL），并回流加热12小时。真空除去溶剂后，将油状残余物溶解于30mL氯仿中，并通过过滤去除不溶的NaCl。最后，真空浓缩滤液，得到无色油状物丁脒肟（2.950g，28.884mmol，产率50％）。

反应信息

• 作为反应物：
  描述：

  丁脒肟 在 邻硝基苯磺酰氯 作用下， 以 吡啶 为溶剂， 以90%的产率得到N-propylcyanamide
  参考文献：
  名称：

  实用的合成氨酰胺肟的Tiemann重排的N-取代的氰胺。

  摘要：

  通过用苯磺酰氯（TsCl或邻-NsCl）和DIPEA进行mid胺肟的Tiemann重排，可以轻松而通用地合成各种N-取代的氰胺。

  DOI：

  10.1021/ol403645y
• 作为产物：
  描述：

  丁腈 在 sodium hydroxide 、 盐酸羟胺 、 水 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以64%的产率得到丁脒肟
  参考文献：
  名称：

  2-（溴二氟甲基）苯并恶唑和5-（溴二氟甲基）-1,2,4-恶二唑的合成

  摘要：

  报道了CF 2 Br-取代的杂环的简便合成。2-（溴二氟甲基）苯并唑（制备2）在两个步骤中由2-氨基苯酚（的反应达到3）与CF 2 BrCO 2的Et，得到酰胺（4），接着环化4与PPA，得到2。5-（溴二氟甲基）-1，2，4-恶二唑（6a–c）是通过mid胺肟（5a–c）与CF 2 BrCO 2 Et一步反应制备的。这些CF 2在正在进行的具有CF 2取代的HIV逆转录酶抑制剂的合成研究中，Br-取代的杂环是中间体。

  DOI：

  10.1016/s0022-1139(99)00007-x

文献信息

• Design, synthesis and biological evaluation of (E)-5-styryl-1,2,4-oxadiazoles as anti-tubercular agents
  作者：Abhay Atmaram Upare、Pradip K. Gadekar、H. Sivaramakrishnan、Nishigandha Naik、Vijay M. Khedkar、Dhiman Sarkar、Amit Choudhari、S. Mohana Roopan

  DOI：10.1016/j.bioorg.2019.01.054

  日期：2019.5

  Cinnamic acid and its derivatives are known for anti-tubercular activity. The present study reports the synthesis of cinnamic acid derivatives via bioisosteric replacement of terminal carboxylic acid with "oxadiazole". A series of cinnamic acid derivatives (styryl oxadiazoles) were designed and synthesized in good yields by reaction of substituted cinnamic acids (2, 15a-15s) with amidoximes. The synthesized

  肉桂酸及其衍生物具有抗结核活性。本研究报道了通过用“恶二唑”对末端羧酸进行生物等位取代来合成肉桂酸衍生物。通过取代肉桂酸（2，15a-15s）与a肟的反应，设计并合成了一系列肉桂酸衍生物（苯乙烯基恶二唑），并以高收率合成。体外评估了合成的苯乙烯基恶二唑类药物对结核分枝杆菌（Mtb）H37Ra菌株的抗结核活性。结构-活性关系（SAR）研究确定了几种具有混合抗结核特性的化合物。化合物32显示出有效的抗结核活性（IC50 = 0.045 µg / mL）。
• Prodrugs of imidazole carboxylic acids as angiotensin II receptor
  申请人：E. I. Du Pont de Nemours and Company

  公开号：US05310929A1

  公开（公告）日：1994-05-10

  Prodrugs of imidazole carboxylic acids which are AII antagonists useful in treating hypertension, pharmaceutical compositions thereof and a method of treating hypertension using such prodrugs are disclosed.

  咪唑羧酸的前药是AII拮抗剂，对治疗高血压有用，公开了这些前药的药物组合物以及使用这些前药治疗高血压的方法。
• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150368278A1

  公开（公告）日：2015-12-24

  The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

  本发明提供了由任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物及其药学上可接受的组合物所包含的范围，或其亚属所包含的范围。本发明还提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来治疗FAAH介导的疾病、紊乱或症状的方法。此外，本发明提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来抑制FAAH的方法。
• [EN] OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'OXADIAZOLE
  申请人：REMYND NV

  公开号：WO2015140130A1

  公开（公告）日：2015-09-24

  The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

  本发明涉及式(I)或(II)的化合物或其立体异构体、对映体、消旋体或互变异构体，其中R1、R2、R3、L1、L2、L3、L4、L5和n的含义与权利要求和说明中定义的含义相同。本发明还涉及包含这些化合物的组合物，特别是药物，以及利用这些化合物和组合物预防和/或治疗代谢紊乱和/或神经退行性疾病和/或蛋白质错折性疾病的用途。
• [EN] PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE<br/>[FR] PIPÉRIDINYLPYRAZOLOPYRIMIDINONES ET LEUR UTILISATION
  申请人：BAYER PHARMA AG

  公开号：WO2016071216A1

  公开（公告）日：2016-05-12

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代哌啶基吡唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者的急性和复发性出血，其中出血与从重经期出血、产后出血、出血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。